AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
nedocromil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiallergics, cromoglicic acid derivatives | 1889 | 69049-73-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with ASTHMA, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 10.40 | mg | N |
| 8 | mg | Inhal.aerosol |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.63 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 3 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.43 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 10.20 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.11 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.90 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 20 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -2.057 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 5.508 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.216 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.146 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 27.450 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 30.930 | % | High | 1 |
| herg | hERG pIC50 | 4.430 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.611 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.451 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 14.290 | % | High | 1 |
| kinase-safety-class | ACVR1B,ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,DYRK3,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,HIPK2,IKBKB,IRAK1,ITK,JAK1,JAK2,KDR,KIT,MAP2K6,MAP3K1,MAP3K10,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MKNK1,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PIM3,PRKAA1,PRKCD,PRKDC,PTK2,SGK1,SIK2,SIK3,STK17A,STK33,SYK,TEK,TGFBR1,TTK,UHMK1,ULK1,ULK2,ZAP70 | 86 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,MAP2K3,MAP2K6,MAP3K14,MAPK7,MTOR,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM3,PRKDC,SIK2,STK33,TEK,TGFBR1,TTK,ZAP70 | 28 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 0.414 | High | 1 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.168 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 1.510 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 35.250 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.045 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 18.960 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.008 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 3.062 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 88.450 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 14.750 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 944.061 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 30, 1992 | FDA | KING PHARMS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | R01AC07 | RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Antiallergic agents, excl. corticosteroids |
| ATC | R03BC03 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS Antiallergic agents, excl. corticosteroids |
| ATC | S01GX04 | SENSORY ORGANS OPHTHALMOLOGICALS DECONGESTANTS AND ANTIALLERGICS Other antiallergics |
| FDA PE | N0000175628 | Decreased Histamine Release |
| FDA EPC | N0000175630 | Mast Cell Stabilizer |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:49167 | anti-asthmatic drug |
| CHEBI has role | CHEBI:50857 | anti-allergic agent |
| CHEBI has role | CHEBI:65023 | anti-asthmatic agent |
| CHEBI has role | CHEBI:77715 | nasal decongestant |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| MeSH PA | D000082142 | Mast Cell Stabilizers |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D007155 | Immunologic Factors |
| MeSH PA | D018926 | Anti-Allergic Agents |
| MeSH PA | D018927 | Anti-Asthmatic Agents |
| MeSH PA | D019141 | Respiratory System Agents |
Related Drugs by ATC class:
R01AC Antiallergic agents, excl. corticosteroids 7 drugs
R03BC Antiallergic agents, excl. corticosteroids 1 drug
S01GX Other antiallergics 12 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Asthma | indication | 195967001 | DOID:2841 |
| Asthma management | indication | 406162001 | |
| Allergic conjunctivitis | indication | 473460002 | DOID:11204 |
| Ocular Itching | indication | ||
| Bronchospasm Prevention | off-label use |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 1.51 | acidic |
| pKa2 | 3.02 | acidic |
| pKa3 | 4.8 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Cysteinyl leukotriene receptor 1 | GPCR | WOMBAT-PK | |||||||
| G-protein coupled receptor 35 | GPCR | AGONIST | EC50 | 6.01 | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| 4023599 | VUID |
| N0000021604 | NUI |
| D00527 | KEGG_DRUG |
| 69049-74-7 | SECONDARY_CAS_RN |
| 4020726 | VANDF |
| 4023599 | VANDF |
| C0068483 | UMLSCUI |
| CHEBI:7492 | CHEBI |
| CHEMBL746 | ChEMBL_ID |
| DB00716 | DRUGBANK_ID |
| CHEMBL915 | ChEMBL_ID |
| D017835 | MESH_DESCRIPTOR_UI |
| 50294 | PUBCHEM_CID |
| 7607 | IUPHAR_LIGAND_ID |
| 5420 | INN_ID |
| 0B535E0BN0 | UNII |
| 266663 | RXNORM |
| 5159 | MMSL |
| d03112 | MMSL |
| 003747 | NDDF |
| 003748 | NDDF |
| 108627004 | SNOMEDCT_US |
| 108629001 | SNOMEDCT_US |
| 372519004 | SNOMEDCT_US |
Pharmaceutical products:
None